The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 22, 2012

Filed:

Aug. 30, 2007
Applicants:

Lluis Ribas DE Pouplana, Barcelona, ES;

Teresa Bori Sanz, Barcelona, ES;

Manuel Castro DE Moura, Lloret de Mar, ES;

Renaud Geslain, Barcelona, ES;

Inventors:

Lluis Ribas De Pouplana, Barcelona, ES;

Teresa Bori Sanz, Barcelona, ES;

Manuel Castro De Moura, Lloret de Mar, ES;

Renaud Geslain, Barcelona, ES;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/48 (2006.01); C12Q 1/02 (2006.01); C12N 9/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

The method comprising: a) obtaining a gene sequence codifying a naturally occurring aminoacyl-tRNA synthetase; b) engineering the gene codifying for said aminoacyl-tRNA synthetase, resulting into an aminoacyl-tRNA synthetase with a defective activity, with the proviso that the engineering does not affect the functionality of the catalytic site of the enzyme; c) cloning the gene resulting from step (b) in an expression vector; d) transforming isolated mammalian cells with the expression vector resulting from step (c); e) growing the recombinant cells resulting from step (d) in a nutrient medium under conditions which allow the expression of the engineered aminoacyl-tRNA synthetase, resulting the expression into cell death or a decrease in the rate of cell division; f) providing a substance to be tested to the medium resulting from step (e); and g) analyzing the resulting cell growth, wherein if there is an increase in cell growth, then the substance selectively inhibits the activity of the engineered aminoacyl-tRNA synthetase and does not affect to its cellular ortholog, resulting in that said substance is a candidate to drug.


Find Patent Forward Citations

Loading…